# Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

Source: https://onco.cc/trials/nct06940388/  
OnCo record `nct06940388` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab in colorectal cancer, run by brenner baruch, now recruiting.

## Summary

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. is a phase 2, randomised interventional study registered as NCT06940388 by brenner baruch, with a registry enrolment figure of 134 participants, started 2025-07-23 and due to reach its primary completion in 2029-08. Interventions recorded: Tislelizumab; Total neoadjuvant therapy (TNT). Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: 3-year total mesorectal excision (TME) free survival rates. Colorectal eligibility wording from the registry: "* No prior chemotherapy, immunotherapy, radiotherapy or surgery for rectal cancer". Sites: Germany, Israel. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TOTAL
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06940388
- Phase: 2
- Setting: Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II Study (The TOTAL Trial)
- Sponsor: brenner baruch
- Enrolled: 134

## Sources

- ClinicalTrials.gov NCT06940388: https://clinicaltrials.gov/study/NCT06940388

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06940388.json